** RBC Capital markets upgrades drugmaker Neurocrine Biosciences NBIX.O to "outperform" from "sector perform", trims PT to $137 from $138

** Brokerage expects NBIX's commercial franchise, particularly Ingrezza, to remain solid and durable in the long term, with relatively low exposure to FDA or tariff concerns

** Ingrezza is approved for treating involuntary movements in the face, tongue or other body parts related to Huntington's disease, a genetic brain disorder

** Brokerage sees potential upside in NBIX's pipeline, particularly with experimental drug osavampator, which has shown favorable antidepressive effects and says it could have a potential market size of $1.8 billion if successful

** As of last close, NBIX stock down 33.4% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))